TYRA News and Press, Tyra Biosciences Inc. From 09/12/23

Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference PR Newswire CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision...

2023-08-29 18:30:23 ET Summary Tyra's net loss continues to improve in Q2 2023. TYRA-300 has been granted Orphan Drug Designation status by the FDA recently, continuing its progression to market. Tyra's substantial cash reserves and ongoing trials support the development of it...

2023-08-11 16:23:04 ET More on Tyra Biosciences Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules Tyra Biosciences gets FDA orphan drug designation for dwarfism therapy Tyra Biosciences soars over 50% on public debut Precision oncolog...

Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights PR Newswire -Orphan Drug Designation granted to TYRA-300 for achondroplasia- - SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B - -TYRA-200 Phase 1 study o...

2023-08-01 10:23:02 ET Tyra Biosciences ( NASDAQ: TYRA ) said that the US Food and Drug Administration has granted orphan drug status to its lead drug candidate TYRA-300 in the treatment of achondroplasia, the most common form of dwarfism. The biotech company said it is prepar...

Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia PR Newswire CARLSBAD, Calif. , Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing...

2023-06-01 05:25:45 ET Summary TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not have clinical data yet. Tyra Biosciences ( TYRA ) develops precision medicines usin...

2023-05-04 18:14:03 ET Tyra Biosciences press release ( NASDAQ: TYRA ): Q1 GAAP EPS of -$0.28 beats by $0.09 . As of March 31, 2023, TYRA had cash and cash equivalents of $241.7 million that will support TYRA through important clinical and operational milestones over a...

Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights PR Newswire -SURF301 Phase 1/2 oncology study continues to advance- - Expanded TYRA-300 clinical development into achondroplasia- -IND for TYRA-200 cleared with Phase 1 study on track ...

Tyra Biosciences to Participate in Upcoming Investor Conferences PR Newswire CARLSBAD, Calif. , March 29, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medic...